{"id":1007020,"date":"2026-09-30T08:06:48","date_gmt":"2026-09-30T12:06:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/"},"modified":"2026-09-30T08:06:48","modified_gmt":"2026-09-30T12:06:48","slug":"nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/","title":{"rendered":"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe"},"content":{"rendered":"<h2>\nNUC-7738 is protected by over 85 issued patents worldwide<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">EDINBURGH, United Kingdom, Sept.  30, 2026  (GLOBE NEWSWIRE) &#8212; NuCana plc (NASDAQ: NCNA) (\u201cNuCana\u201d or the \u201cCompany\u201d) announced that the European Patent Office (\u201cEPO\u201d) has granted an important patent covering the composition of matter for NUC-7738.<\/p>\n<p align=\"justify\">This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemical structure of NUC-7738, NuCana\u2019s novel anti-cancer agent currently being evaluated in the Phase 2 part of a Phase 1\/2 clinical study (NuTide:701) in combination with Keytruda<sup>\u00ae<\/sup> (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma.<\/p>\n<p align=\"justify\">Securing this patent represents an important milestone for NuCana, further strengthening the Company\u2019s long-term global intellectual property strategy and the potential commercial protection of NUC-7738.<\/p>\n<p align=\"justify\">Hugh S. Griffith, NuCana\u2019s Founder and Chief Executive Officer, said: \u201cWe are delighted that the EPO has granted this important new patent, which further strengthens the intellectual property protection of NUC-7738 and reflects the strength and novelty of our science. This composition-of-matter patent is a critical addition to our global patent estate for NUC-7738, which now spans over 85 issued patents worldwide, and builds upon similar composition-of-matter patents previously granted in both the United States and China. This underscores our commitment to protecting NUC-7738&#8217;s long-term commercial potential across all major markets. With cash resources expected to fund our planned operations into 2029, we believe we are well positioned to advance the clinical development of NUC-7738 and to deliver on a number of important milestones over the remainder of 2026 as we work to bring meaningful new treatment options to patients with cancer.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About NuCana<\/strong>\n      <\/p>\n<p align=\"justify\">NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana\u2019s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1\/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a targeted thymidylate synthase (\u201cTS\u201d) inhibitor designed to overcome key pharmacological limitations associated with other TS inhibitors. NUC-3373 has recently been evaluated in a Phase 1b\/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer, and NuCana is currently evaluating further characterization of mode of action and target indications for further clinical studies of NUC-3373.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release may contain \u201cforward-looking\u201d statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of the Company. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company\u2019s planned and ongoing clinical studies for the Company\u2019s product candidates and the potential advantages of those product candidates, including NUC-7738 and NUC-3373; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company\u2019s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company\u2019s current cash and cash equivalents to fund its planned operations into 2029. In some cases, you can identify forward-looking statements by terminology such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company\u2019s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to raise additional capital sufficient to fund our planned operations and the risks and uncertainties set forth in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 19, 2026, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company\u2019s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.<\/em><\/p>\n<p>For more information, please contact:<\/p>\n<p>NuCana plc<br \/>Hugh S. Griffith<br \/>Chief Executive Officer<br \/>+44 131-357-1111 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MFO8edgh-8UMXTm4xtGXWSGscIPUUOjrJ_wHGaHSIy2_D910TK2-byjNzqqfK1RFF9BB1K4g68WQn8bJDfd4yQ==\" rel=\"nofollow\" target=\"_blank\">info@nucana.com<\/a><\/p>\n<p>ICR Healthcare<br \/>Chris Brinzey<br \/>+1 339-970-2843<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=19rzU03Z3VBu9qDQbYfV0wtJp5PZwdTfWEgJ9shuhtxxtWwif1dz3POoH15XUOYbM4bK9Fmmdiv7vZx1j6Y7e3frlDsOBSrxhrMfX9Hvfh4Xf4s1VXi0PKaHQCrYVLmG\" rel=\"nofollow\" target=\"_blank\">Chris.Brinzey@ICRHealthcare.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWU3YWZlNTQtNGYxNy00ZjlkLWFiMDMtMGM2NWQ0Y2M4OWQ1LTExMDI4NjItMjAyNi0wOS0zMC1lbg==\/tiny\/NuCana-plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NUC-7738 is protected by over 85 issued patents worldwide EDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) &#8212; NuCana plc (NASDAQ: NCNA) (\u201cNuCana\u201d or the \u201cCompany\u201d) announced that the European Patent Office (\u201cEPO\u201d) has granted an important patent covering the composition of matter for NUC-7738. This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemical structure of NUC-7738, NuCana\u2019s novel anti-cancer agent currently being evaluated in the Phase 2 part of a Phase 1\/2 clinical study (NuTide:701) in combination with Keytruda\u00ae (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma. Securing this patent represents an important milestone for NuCana, further strengthening the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1007020","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NUC-7738 is protected by over 85 issued patents worldwide EDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) &#8212; NuCana plc (NASDAQ: NCNA) (\u201cNuCana\u201d or the \u201cCompany\u201d) announced that the European Patent Office (\u201cEPO\u201d) has granted an important patent covering the composition of matter for NUC-7738. This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemical structure of NUC-7738, NuCana\u2019s novel anti-cancer agent currently being evaluated in the Phase 2 part of a Phase 1\/2 clinical study (NuTide:701) in combination with Keytruda\u00ae (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma. Securing this patent represents an important milestone for NuCana, further strengthening the &hellip; Continue reading &quot;NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T12:06:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe\",\"datePublished\":\"2026-09-30T12:06:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/\"},\"wordCount\":930,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/\",\"name\":\"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=\",\"datePublished\":\"2026-09-30T12:06:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/","og_locale":"en_US","og_type":"article","og_title":"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe - Market Newsdesk","og_description":"NUC-7738 is protected by over 85 issued patents worldwide EDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) &#8212; NuCana plc (NASDAQ: NCNA) (\u201cNuCana\u201d or the \u201cCompany\u201d) announced that the European Patent Office (\u201cEPO\u201d) has granted an important patent covering the composition of matter for NUC-7738. This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemical structure of NUC-7738, NuCana\u2019s novel anti-cancer agent currently being evaluated in the Phase 2 part of a Phase 1\/2 clinical study (NuTide:701) in combination with Keytruda\u00ae (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma. Securing this patent represents an important milestone for NuCana, further strengthening the &hellip; Continue reading \"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-30T12:06:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe","datePublished":"2026-09-30T12:06:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/"},"wordCount":930,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/","name":"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=","datePublished":"2026-09-30T12:06:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjQ3MiM3ODY3NTM5IzIwOTEyOTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-announces-grant-of-composition-of-matter-patent-for-nuc-7738-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1007020"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007020\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1007020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1007020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1007020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}